Published in J Clin Endocrinol Metab on June 01, 2010
Hormone replacement therapy and physical function in healthy older men. Time to talk hormones? Endocr Rev (2012) 1.01
Four Thrombotic Events Over 5 Years, Two Pulmonary Emboli and Two Deep Venous Thrombosis, When Testosterone-HCG Therapy Was Continued Despite Concurrent Anticoagulation in a 55-Year-Old Man With Lupus Anticoagulant. J Investig Med High Impact Case Rep (2016) 0.77
Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA (2002) 80.37
Screening and prostate-cancer mortality in a randomized European study. N Engl J Med (2009) 35.94
Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst (2006) 9.91
Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med (2008) 8.14
Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab (2010) 7.15
American Cancer Society guideline for the early detection of prostate cancer: update 2010. CA Cancer J Clin (2010) 6.45
Testosterone therapy in adult men with androgen deficiency syndromes: an endocrine society clinical practice guideline. J Clin Endocrinol Metab (2006) 5.58
Low serum testosterone and mortality in older men. J Clin Endocrinol Metab (2007) 4.27
Prostate specific antigen best practice statement: 2009 update. J Urol (2009) 3.95
Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: European prospective investigation into cancer in Norfolk (EPIC-Norfolk) Prospective Population Study. Circulation (2007) 3.71
Clinical review 1: Adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis. J Clin Endocrinol Metab (2010) 3.40
Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial. JAMA (2006) 3.32
Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials. J Gerontol A Biol Sci Med Sci (2005) 3.14
Androgens and cardiovascular disease. Endocr Rev (2003) 2.71
Persistent intraprostatic androgen concentrations after medical castration in healthy men. J Clin Endocrinol Metab (2006) 2.57
Androgens and coronary artery disease. Endocr Rev (2003) 2.26
Performance of prostate cancer prevention trial risk calculator in a contemporary cohort screened for prostate cancer and diagnosed by extended prostate biopsy. J Urol (2009) 1.81
The response of metastatic adenocarcinoma of the prostate to exogenous testosterone. J Urol (1981) 1.55
Endogenous sex hormones and cardiovascular disease incidence in men. Ann Intern Med (2006) 1.22
Exogenous testosterone (T) alone or with finasteride increases physical performance, grip strength, and lean body mass in older men with low serum T. J Clin Endocrinol Metab (2004) 3.02
Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone. J Clin Endocrinol Metab (2004) 2.39
Testosterone treatment and mortality in men with low testosterone levels. J Clin Endocrinol Metab (2012) 2.29
The effect of 5alpha-reductase inhibition with dutasteride and finasteride on semen parameters and serum hormones in healthy men. J Clin Endocrinol Metab (2007) 1.53
Clinical practice patterns in the assessment and management of low testosterone in men: an international survey of endocrinologists. Clin Endocrinol (Oxf) (2014) 1.52
Intratesticular androgens and spermatogenesis during severe gonadotropin suppression induced by male hormonal contraceptive treatment. J Androl (2007) 1.45
Serum insulin-like factor 3 is highly correlated with intratesticular testosterone in normal men with acute, experimental gonadotropin deficiency stimulated with low-dose human chorionic gonadotropin: a randomized, controlled trial. Fertil Steril (2012) 1.44
Testosterone administration suppresses adiponectin levels in men. J Androl (2004) 1.24
Low-dose human chorionic gonadotropin maintains intratesticular testosterone in normal men with testosterone-induced gonadotropin suppression. J Clin Endocrinol Metab (2005) 1.19
A single dose of the potent gonadotropin-releasing hormone antagonist acyline suppresses gonadotropins and testosterone for 2 weeks in healthy young men. J Clin Endocrinol Metab (2004) 1.13
Assessment and management of low bone density in inflammatory bowel disease and performance of professional society guidelines. Inflamm Bowel Dis (2011) 1.11
Testosterone gel combined with depomedroxyprogesterone acetate is an effective male hormonal contraceptive regimen and is not enhanced by the addition of a GnRH antagonist. J Clin Endocrinol Metab (2006) 1.05
Determinants of the rate and extent of spermatogenic suppression during hormonal male contraception: an integrated analysis. J Clin Endocrinol Metab (2008) 1.05
Male hypogonadism : an update on diagnosis and treatment. Treat Endocrinol (2005) 1.00
Intratesticular testosterone concentrations comparable with serum levels are not sufficient to maintain normal sperm production in men receiving a hormonal contraceptive regimen. J Androl (2004) 1.00
Acyline: the first study in humans of a potent, new gonadotropin-releasing hormone antagonist. J Clin Endocrinol Metab (2002) 0.91
Acceptability of a combination testosterone gel and depomedroxyprogesterone acetate male contraceptive regimen. Contraception (2007) 0.90
Preoperative supraphysiological testosterone in older men undergoing knee replacement surgery. J Am Geriatr Soc (2002) 0.88
Serum 17-hydroxyprogesterone strongly correlates with intratesticular testosterone in gonadotropin-suppressed normal men receiving various dosages of human chorionic gonadotropin. Fertil Steril (2007) 0.85
Relationship between serum gonadotropins and spermatogenic suppression in men undergoing steroidal contraceptive treatment. J Clin Endocrinol Metab (2004) 0.84
Elevated end-of-treatment serum INSL3 is associated with failure to completely suppress spermatogenesis in men receiving male hormonal contraception. J Androl (2007) 0.80
The male contraceptive regimen of testosterone and levonorgestrel significantly increases lean mass in healthy young men in 4 weeks, but attenuates a decrease in fat mass induced by testosterone alone. J Clin Endocrinol Metab (2003) 0.79
Clinical decisions. Testosterone-replacement therapy. N Engl J Med (2014) 0.79
Male hypogonadism in the primary care clinic. Prim Care (2003) 0.78
Male hormonal contraception: an update on research progress. Treat Endocrinol (2002) 0.77
Postmenopausal hormone replacement therapy and major clinical outcomes: a focus on cardiovascular disease, osteoporosis, dementia, and breast and endometrial neoplasia. Am J Manag Care (2002) 0.75
Pocket change: a simple educational intervention increases hospitalist documentation of comorbidities and improves hospital quality performance measures. Qual Manag Health Care (2015) 0.75
A multidisciplinary care pathway significantly increases the number of early morning discharges in a large academic medical center. Qual Manag Health Care (2014) 0.75
"Can we just stop and talk?" patients value verbal communication about discharge care plans. J Hosp Med (2012) 0.75
Male hormonal contraception. Expert Opin Emerg Drugs (2004) 0.75